Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Receives $36.60 Consensus Price Target from Analysts

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) has received an average recommendation of “Buy” from the five ratings firms that are presently covering the company, MarketBeat Ratings reports. Five research analysts have rated the stock with a buy recommendation. The average twelve-month price target among brokers that have updated their coverage on the stock in the last year is $36.60.

Several brokerages have issued reports on KNSA. Evercore ISI raised their price objective on shares of Kiniksa Pharmaceuticals from $30.00 to $35.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 30th. JPMorgan Chase & Co. upped their price objective on Kiniksa Pharmaceuticals from $39.00 to $40.00 and gave the company an “overweight” rating in a report on Tuesday, November 5th. Finally, Jefferies Financial Group initiated coverage on shares of Kiniksa Pharmaceuticals in a research report on Friday, September 13th. They issued a “buy” rating and a $40.00 target price for the company.

Insiders Place Their Bets

In related news, COO Eben Tessari sold 17,000 shares of the firm’s stock in a transaction dated Tuesday, October 15th. The stock was sold at an average price of $26.87, for a total value of $456,790.00. Following the sale, the chief operating officer now directly owns 109,975 shares of the company’s stock, valued at $2,955,028.25. This trade represents a 13.39 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, insider John F. Paolini sold 60,692 shares of the business’s stock in a transaction dated Tuesday, September 3rd. The stock was sold at an average price of $26.12, for a total value of $1,585,275.04. Following the transaction, the insider now directly owns 52,038 shares of the company’s stock, valued at approximately $1,359,232.56. The trade was a 53.84 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 95,192 shares of company stock worth $2,479,390 over the last ninety days. Corporate insiders own 54.57% of the company’s stock.

Institutional Trading of Kiniksa Pharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Quarry LP acquired a new stake in shares of Kiniksa Pharmaceuticals during the 3rd quarter valued at $50,000. CWM LLC grew its holdings in shares of Kiniksa Pharmaceuticals by 443.0% during the third quarter. CWM LLC now owns 2,449 shares of the company’s stock worth $61,000 after purchasing an additional 1,998 shares during the last quarter. nVerses Capital LLC bought a new position in Kiniksa Pharmaceuticals in the 3rd quarter valued at approximately $80,000. Lazard Asset Management LLC acquired a new stake in Kiniksa Pharmaceuticals during the 1st quarter worth approximately $71,000. Finally, Ashton Thomas Private Wealth LLC bought a new stake in Kiniksa Pharmaceuticals during the 2nd quarter worth approximately $100,000. Institutional investors own 53.95% of the company’s stock.

Kiniksa Pharmaceuticals Trading Down 1.1 %

KNSA stock opened at $22.08 on Wednesday. The business’s 50 day simple moving average is $24.02 and its 200 day simple moving average is $22.92. Kiniksa Pharmaceuticals has a 1-year low of $15.82 and a 1-year high of $28.15. The firm has a market capitalization of $1.59 billion, a PE ratio of -159.42 and a beta of 0.35.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last issued its quarterly earnings data on Tuesday, October 29th. The company reported ($0.18) earnings per share for the quarter, missing the consensus estimate of ($0.01) by ($0.17). The company had revenue of $112.21 million during the quarter, compared to the consensus estimate of $111.51 million. Kiniksa Pharmaceuticals had a negative net margin of 2.36% and a negative return on equity of 7.31%. Kiniksa Pharmaceuticals’s revenue for the quarter was up 67.4% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.20) earnings per share. As a group, sell-side analysts predict that Kiniksa Pharmaceuticals will post -0.55 EPS for the current fiscal year.

About Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.